Bexsero Description

Concise Prescribing Info Full Prescribing Info Contents Description Action Indications/Uses Dosage/Direction for Use Overdosage Contraindications Special Precautions Use In Pregnancy & Lactation Adverse Reactions Drug Interactions Caution For Usage Storage MIMS Class ATC Classification Regulatory Classification Presentation/Packing

The information highlighted (if any) are the most recent updates for this brand.

Full Prescribing Info

Description

The vaccine is a white opalescent liquid suspension.
1 dose (0.5 mL) contains: Recombinant Neisseria meningitidis group B NHBA fusion protein ^{1, 2, 3} 50 micrograms; Recombinant Neisseria meningitidis group B NadA protein ^{1, 2, 3} 50 micrograms; Recombinant Neisseria meningitidis group B fHbp fusion protein ^{1, 2, 3} 50 micrograms; Outer membrane vesicles (OMV) from Neisseria meningitidis group B strain NZ98/254 measured as amount of total protein containing the PorA P1.4 ² 25 micrograms.
¹produced in E. coli cells by recombinant DNA technology.
²Adsorbed on aluminium hydroxide (0.5 mg Al³⁺).
³NHBA (Neisserial Heparin Binding Antigen), NadA (Neisseria adhesin A), fHbp (factor H binding protein).
Excipients/Inactive Ingredients: Sodium chloride, Histidine, Sucrose, Water for injections.
Residues: Kanamycin (kanamycin is used in early manufacturing process and is removed during the later stages of manufacture. If present, kanamycin levels in the final vaccine are less than 0.01 micrograms per dose).

vaccine, meningococcal

Manufacturer:

GlaxoSmithKline Vaccines

Distributor:

GlaxoSmithKline